

Peter H Sykes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/848294/publications.pdf>

Version: 2024-02-01

80
papers

2,275
citations

304602

22
h-index

233338

45
g-index

82
all docs

82
docs citations

82
times ranked

3063
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting regression of cervical intraepithelial neoplasia grade 2 in women under 25 years. American Journal of Obstetrics and Gynecology, 2022, 226, 222.e1-222.e13.	0.7	9
2	Collagen I dysregulation is pivotal for ovarian cancer progression. Tissue and Cell, 2022, 74, 101704.	1.0	4
3	Use of direct oral anticoagulants for postoperative venous thromboembolism prophylaxis after surgery for gynecologic malignancies. International Journal of Gynecological Cancer, 2022, 32, 189-194.	1.2	3
4	The Anti-Proliferative Effect of PI3K/mTOR and ERK Inhibition in Monolayer and Three-Dimensional Ovarian Cancer Cell Models. Cancers, 2022, 14, 395.	1.7	8
5	Blimp-1 is a prognostic indicator for progression of cervical intraepithelial neoplasia grade 2. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1991-2002.	1.2	3
6	Deciphering Biophysical Modulation in Ovarian Cancer Cells. Cell Biochemistry and Biophysics, 2021, 79, 375-386.	0.9	4
7	Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecologic Oncology, 2021, 161, 143-151.	0.6	46
8	A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. Gynecologic Oncology, 2021, 163, 72-78.	0.6	17
9	Reaching under-€screened/never-€screened indigenous peoples with human papilloma virus self-€testing: A community-€based cluster randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2021, 61, 135-141.	0.4	23
10	Low-€grade serous ovarian carcinoma: A comprehensive literature review. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 27-33.	0.4	6
11	New approaches to cancer care in a COVID-19 world. Lancet Oncology, The, 2020, 21, e339-e340.	5.1	18
12	Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. International Journal of Gynecological Cancer, 2020, 30, 1748-1756.	1.2	24
13	Extracellular biophysical environment: Guilty of being a modulator of drug sensitivity in ovarian cancer cells. Biochemical and Biophysical Research Communications, 2020, 527, 180-186.	1.0	4
14	Evaluation of guidelines for observational management of cervical intraepithelial neoplasia 2 in young women. American Journal of Obstetrics and Gynecology, 2020, 223, 408.e1-408.e11.	0.7	7
15	Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors. Applied Sciences (Switzerland), 2020, 10, 2343.	1.3	2
16	A Doctrine of Ovarian Cancer Translational Research Needs Revisiting. International Journal of Cancer Management, 2020, 13, .	0.2	0
17	Impact of human papillomavirus vaccination on rates of abnormal cervical cytology and histology in young New Zealand women. New Zealand Medical Journal, 2020, 133, 72-84.	0.5	2
18	Trends in the diagnosis of high-grade cervical abnormalities in young women in the post-vaccination era. New Zealand Medical Journal, 2020, 133, 50-63.	0.5	2

#	ARTICLE	IF	CITATIONS
19	Trends in the overall survival rates in women with advanced ovarian cancer in a single tertiary centre in New Zealand. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019, 59, 861-866.	0.4	0
20	Tumour Initiation: a Discussion on Evidence for a "Load-Trigger" Mechanism. Cell Biochemistry and Biophysics, 2019, 77, 293-308.	0.9	14
21	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecologic Oncology, 2019, 154, 531-538.	0.6	49
22	Pathological process has a crucial role in sentinel node biopsy for vulvar cancer. Gynecologic Oncology, 2019, 153, 292-296.	0.6	12
23	The extracellular topographical environment influences ovarian cancer cell behaviour. Biochemical and Biophysical Research Communications, 2019, 508, 1188-1194.	1.0	6
24	Acceptability of self-taken vaginal HPV sample for cervical screening among an under-screened Indigenous population. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019, 59, 301-307.	0.4	34
25	Patterns of referral and uptake of Breast Cancer (BRCA) gene testing of eligible women with ovarian cancer in New Zealand. New Zealand Medical Journal, 2019, 132, 26-35.	0.5	0
26	Does the endometrial gene expression of fertile women vary within and between cycles?. Human Reproduction, 2018, 33, 452-463.	0.4	15
27	Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells. Cancer Letters, 2018, 420, 168-181.	3.2	7
28	Changes in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013-2016). Papillomavirus Research (Amsterdam, Netherlands), 2018, 6, 77-82.	4.5	14
29	PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary.. Journal of Clinical Oncology, 2018, 36, 5524-5524.	0.8	8
30	Cell-like features imprinted in the physical nano- and micro-topography of the environment modify the responses to anti-cancer drugs of endometrial cancer cells. Biofabrication, 2017, 9, 015017.	3.7	14
31	Initial observation of CIN2 does not appear to reduce quality of life in women under 25 years of age. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 473-478.	0.4	4
32	Enhanced Recovery After Surgery for Suspected Ovarian Malignancy. International Journal of Gynecological Cancer, 2017, 27, 1046-1050.	1.2	11
33	Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence. Gynecologic Oncology, 2017, 146, 273-278.	0.6	15
34	Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1224.	3.8	271
35	Cytotoxicity and cellular uptake of different sized gold nanoparticles in ovarian cancer cells. Nanotechnology, 2017, 28, 475101.	1.3	44
36	Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. BMJ Open, 2017, 7, e017576.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Observational Management of CIN 2 in Young Women: A Prospective Multicenter Trial. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 343-347.	0.9	11
38	Seed mediated synthesis of highly mono-dispersed gold nanoparticles in the presence of hydroquinone. <i>Nanotechnology</i> , 2016, 27, 355601.	1.3	19
39	A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models. <i>Oncology and Therapy</i> , 2016, 4, 257-274.	1.0	10
40	Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF- κ B protein. <i>Journal of Ovarian Research</i> , 2016, 9, 84.	1.3	31
41	The characteristics of Ishikawa endometrial cancer cells are modified by substrate topography with cell-like features and the polymer surface. <i>International Journal of Nanomedicine</i> , 2015, 10, 4883.	3.3	12
42	Resveratrol, Acetyl-Resveratrol, and Polydatin Exhibit Antigrowth Activity against 3D Cell Aggregates of the SKOV-3 and OVCAR-8 Ovarian Cancer Cell Lines. <i>Obstetrics and Gynecology International</i> , 2015, 2015, 1-14.	0.5	22
43	A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput format. <i>Journal of Ovarian Research</i> , 2015, 8, 43.	1.3	2
44	Wrong place at the wrong time: A case of cervical embryonal rhabdomyosarcoma in pregnancy. <i>Gynecologic Oncology Reports</i> , 2015, 12, 77-79.	0.3	6
45	Uterine cancer: exploring access to services in the public health system. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2014, 54, 457-461.	0.4	6
46	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S67-S72.	1.2	75
47	Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand. <i>BMC Infectious Diseases</i> , 2014, 14, 374.	1.3	8
48	In the secretory endometria of women, luminal epithelia exhibit gene and protein expressions that differ from those of glandular epithelia. <i>Fertility and Sterility</i> , 2014, 102, 307-317.e7.	0.5	20
49	The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5621-TPS5621.	0.8	0
50	Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer. <i>Experimental Cell Research</i> , 2013, 319, 75-87.	1.2	139
51	Retrospective analysis on timeframes of referral, diagnosis and treatment of patients with endometrial carcinomas in Dunedin Hospital, 2008-2011. <i>New Zealand Medical Journal</i> , 2013, 126, 84-95.	0.5	3
52	Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. <i>Gynecologic Oncology</i> , 2012, 125, 520-525.	0.6	27
53	The Impact of Outpatient Booking Systems on Waiting Times for Investigation of Suspected Cancer: The Case of Post-Menopausal Bleeding. <i>Clinical Ovarian and Other Gynecologic Cancer</i> , 2012, 5, 87-93.	0.1	2
54	Gene and protein expression signature of endometrial glandular and stromal compartments during the window of implantation. <i>Fertility and Sterility</i> , 2012, 97, 1365-1373.e2.	0.5	43

#	ARTICLE	IF	CITATIONS
55	Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. <i>European Journal of Cancer</i> , 2012, 48, 1147-1153.	1.3	86
56	Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. <i>European Journal of Cancer</i> , 2012, 48, 2155-2162.	1.3	33
57	Adrenomedullin interacts with VEGF in endometrial cancer and has varied modulation in tumours of different grades. <i>Gynecologic Oncology</i> , 2012, 125, 214-219.	0.6	16
58	The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer. <i>Journal of Translational Medicine</i> , 2012, 10, 38.	1.8	112
59	Providing care for women with gynaecological malignancy: the need for a coordinated national approach. <i>New Zealand Medical Journal</i> , 2012, 125, 57-65.	0.5	1
60	Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2011, 120, 179-184.	0.6	12
61	Determinants of inequalities in cervical cancer stage at diagnosis and survival in New Zealand. <i>Cancer Causes and Control</i> , 2010, 21, 209-214.	0.8	12
62	Testing for high risk human papilloma virus in the initial follow-up of women treated for high-grade squamous intraepithelial lesions. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2010, 50, 164-167.	0.4	14
63	Improving survival disparities in cervical cancer between Māori and non-Māori women in New Zealand: a national retrospective cohort study. <i>Australian and New Zealand Journal of Public Health</i> , 2010, 34, 193-199.	0.8	23
64	Low Ascorbate Levels Are Associated with Increased Hypoxia-Inducible Factor-1 Activity and an Aggressive Tumor Phenotype in Endometrial Cancer. <i>Cancer Research</i> , 2010, 70, 5749-5758.	0.4	116
65	Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 772-780.	5.1	296
66	Regulation of Vascular Endothelial Growth Factor in endometrial tumour cells by resveratrol and EGCG. <i>Gynecologic Oncology</i> , 2009, 113, 374-378.	0.6	25
67	Primary breast cancer of the vulva: Case report and literature review. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2007, 47, 77-79.	0.4	19
68	Cellular transfer and AFM imaging of cancer cells using Bioimprint. <i>Journal of Nanobiotechnology</i> , 2006, 4, 1.	4.2	44
69	MALIGNANT PROGRESSION OF ANAL INTRA-EPITHELIAL NEOPLASIA. <i>ANZ Journal of Surgery</i> , 2006, 76, 715-717.	0.3	221
70	Does regular cervical screening protect women from microinvasive squamous cell carcinoma of the cervix? A retrospective case-control study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2005, 112, 807-809.	1.1	7
71	Postpartum curettage: An audit of 200 cases. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2005, 45, 368-371.	0.4	24
72	Human papilloma virus is detectable by the Hybrid Capture 2 test in cervical smear samples from women over 40 years of age with high-grade squamous intraepithelial lesions. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2005, 45, 457-459.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Findings and outcome of teenage women referred for colposcopy at Christchurch Women's Hospital, New Zealand. <i>New Zealand Medical Journal</i> , 2005, 118, U1350.	0.5	0
74	Clinical utility of magnetic resonance imaging and the preoperative identification of low risk endometrial cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2004, 44, 419-422.	0.4	4
75	Is there a role for colposcopy in the follow-up of treated low grade squamous intraepithelial lesions?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2004, 44, 574-576.	0.4	1
76	Modulation of vascular endothelial growth factor and thymidine phosphorylase in normal human endometrial stromal cells. <i>Fertility and Sterility</i> , 2004, 82, 1048-1053.	0.5	5
77	High-grade vulval intraepithelial neoplasia (VIN 3): a retrospective analysis of patient characteristics, management, outcome and relationship to squamous cell carcinoma of the vulva 1989-1999. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2002, 42, 75-80.	0.4	39
78	Trophoblastic Differentiation in an Endometrial Carcinoma. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1998, 38, 472-473.	0.4	12
79	Desmoplastic melanoma of the vulva. <i>Pathology</i> , 1997, 29, 241-245.	0.3	12
80	Dermatomyositis and Ovarian Cancer: A Rare Occurrence but a Significant Association. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1994, 34, 616-617.	0.4	0